Plitidepsin (dehydrodidemnin B) is a potent inhibitor of protein synthesis, blocker of G1 and G2 phases in cell cycle and potent antiviral against SARS-CoV-2 in hACE2-293T, Vero E6 cells and models of pneumocyte-like cells (IC90 values are 0.88 nM, 1.76 nM and 3.14 nM, respectively). Plitidepsin also inhibits eukaryotic translation elongation factor 1 alpha 1 (eEF1A) (KD = 80 nM).
In vitro, it inhibits induction of ornithine decarboxylase (ODC), which is essential for cell transformation and proliferation.
In vivo, daily administration of Plitidepsin on mice affected by Ehrlich carcinoma duplicated the animal life-span and decreased the total number of tumor cells by 70-90%. Plitidepsin also reduces viral SARS-CoV-2 replication in the lungs (mouse).
It is recommended to prepare stock solutions in DMSO.
